| Literature DB >> 31281578 |
Yang Zhang1, Yifei Wang1, Mingzhu Li1, Shuyue Liu1, Jialu Yu1, Zhaowei Yan2, Hongli Zhou3.
Abstract
Oviductus ranae is an animal-based traditional Chinese material widely used as tonics in China for hundreds of years. Various bioactive components are present in OR including proteins, amino acids, steroids, fatty acids, phospholipids, nucleosides, vitamins, hydantoins, and mineral elements. These constituents exert a myriad of biological functions such as immunomodulatory, antioxidant, antifatigue, antiaging, estrogen-like, hepatoprotective, hypolipidemic, antiosteoporotic, antidepressant, antitumor, antitussive, expectorant, anti-inflammatory, and antiasthmatic activities. Unlike other traditional Chinese crude drugs recorded in Chinese Pharmacopoeia, OR is seldom prescribed as medicine but often consumed as nutraceuticals to optimize health. In this review, the traditional uses, bioactive constituents, biological functions, and safety properties of OR as functional foods in China were summarized and discussed. It is expected that this review will provide useful information for anyone who is interested in OR.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31281578 PMCID: PMC6589215 DOI: 10.1155/2019/4739450
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1R. dybowskii. The figure was obtained from https://image.baidu.com/, the search keyword was “R. dybowskii”.
Figure 2Morphological changes of the oviduct (Oviductus ranae) from R. dybowskii [20].
Figure 3Diagram of the preparation process of edible Oviductus ranae from dried product.
Bioactive constituents present in Oviductus ranae.
| Class | Chemical ingredients | References |
|---|---|---|
| Mineral elements | K, Na, Ca, Mg, Fe, Mn, Zn, Cu, Sr, Cr, Mo, Se, P, Al, Ba, Ni, Co, V, Ag, Pb, and Cd | [ |
| Amino acids | Asp, Thr, Ser, Glu, Pro, Gly, Ala, Cys, Val, Met, Ile, Leu, Tyr, Phe, His, Lys, Arg, and Trp | [ |
| Proteins | 170, 157, 128, and 49 kDa proteins | [ |
| 116 kDa protein | [ | |
| 66 kDa protein | [ | |
| 53~66 kDa polypeptides or proteins | [ | |
| 20.2 kDa protein | [ | |
| Steroids | Cholesterol | [ |
| 7-Dehydrocholesterol | [ | |
| Cholest-4-ene-3-one | [ | |
| Cholest-5-ene-3 | [ | |
| 3 | [ | |
| Cholesteryl palmitate | [ | |
| Cholestan-3,6-dione | [ | |
| Stigmasterol | [ | |
| Estradiol | [ | |
| Progesterone | [ | |
| Testosterone | [ | |
| Androsterone acetate | [ | |
| Medrogestone | [ | |
| Fatty acids | Heptanoic acid | [ |
| 7-Nonenoic acid | [ | |
| 10-Undecenoic acid | [ | |
| Lauric acid | [ | |
| Ficocerylic acid | [ | |
| Myristic acid | [ | |
| Pentadecanoic acid | [ | |
| Palmitic acid | [ | |
| Palmitoleic acid | [ | |
| Hexadecadienoic acid | [ | |
| 14-Methyl-pentadecanoic acid | [ | |
| Heptadecanoic acid | [ | |
| Stearic acid | [ | |
| Oleic acid | [ | |
| Linoleic acid | [ | |
|
| [ | |
| 11-Octadecenoic acid | [ | |
| 16-Methyl-heptadecanoic acid | [ | |
| Arachidic acid | [ | |
| Eicosadienoic acid | [ | |
| Eicosatrienoic acid | [ | |
| Arachidonic acid | [ | |
|
| [ | |
| Behenic acid | [ | |
| Phospholipids | Sphingomyelin | [ |
| Cephalin | [ | |
| Phosphatidylcholine | [ | |
| Vitamins | Vitamin E | [ |
| Vitamin A | [ | |
| Vitamin D | [ | |
| Vitamin B1 | [ | |
| Vitamin B2 | [ | |
| Vitamin C | [ | |
| Vitamin K | [ | |
|
| [ | |
| Nucleosides | Inosine | [ |
| Hydantoins | 1-Methylhydantoin | [ |
| Others | Polysaccharides | [ |
| Human chorionic gonadotropin | [ | |
| Thyroxin | [ | |
| Triiodothyronine | [ | |
| Parathyroid hormone | [ |
Abbreviations: K: potassium; Na: sodium; Ca: calcium; Mg: magnesium; Fe: ferrum; Mn: manganese; Zn: zinc; Cu: copper; Sr: strontium; Cr: chromium; Mo: molybdenum; Se: selenium; P: phosphorus; Al: aluminum; Ba: barium; Ni: nickel; Co: cobalt; V: vanadium; Ag: silver; Pb: lead; Cd: cadmium; Asp: aspartic acid; Thr: threonine; Ser: serine; Glu: glutamic acid; Pro: proline; Gly: glycine; Ala: alanine; Cys: cysteine; Val: valine; Met: methionine; Ile: isoleucine; Leu: leucine; Tyr: tyrosine; Phe: phenylalanine; His: histidine; Lys: lysine; Arg: arginine; Trp: tryptophan.
Biological functions of Oviductus ranae and its active principles.
| Healthy functions | Active principle/preparation | Model | Dosage | Results | Reference |
|---|---|---|---|---|---|
| Immunomodulatory activities |
| Mice ( | 0.67 and 1.33 g/kg BW, i.g., for 30 days | Enhance lymphocyte proliferation, antibody-producing cells, delayed-type hypersensitivity response, NK cell activity, and phagocytosis of mononuclear macrophages | [ |
|
| Splenic lymphocyte and RAW 264.7 cells ( | 500 | Increase spleen lymphocyte proliferation, IL-2 production, macrophage phagocytosis, and NO production | [ | |
|
| RAW 264.7 cells ( | 500 | Improve macrophage phagocytosis and NO production | [ | |
|
| Splenic lymphocyte and RAW 264.7 cells ( | 50-800 | Increase spleen lymphocyte proliferation, macrophage phagocytosis, and NO production | [ | |
|
| RAW 264.7 cells ( | 10-2000 | Enhance macrophage phagocytosis and productions of IL-1 | [ | |
| Peptide from | Splenic lymphocyte ( | 20-100 mg/mL ( | Increase spleen lymphocyte proliferation and immune organ index | [ | |
| Compound Renshen-Hamayou capsule | Mice ( | 1.5 g/kg BW, i.g., for 45 days | Enhance delayed-type hypersensitivity response and spleen lymphocyte proliferation | [ | |
| Hamayou soft capsule | Healthy male athletes aged from 18 to 24 years ( | Three times a day, 4 g each time, P.O., for 28 days | Increase CD3+, CD4+, and CD4+/CD8+ ratio | [ | |
| Antioxidant activities |
| Mice exposed to cold stress ( | 0.5 and 2.5 g/kg BW, i.g., for 28 days | Increase SOD; decrease MDA | [ |
|
| Young and aging mice ( | 0.45, 1.35, and 2.25 g/kg BW, i.g., for 15, 30, and 45 days, respectively | Upregulate the expression of Cu/Zn-SOD and GPx4 genes | [ | |
| Serum from | H2O2-induced oxidative stress in rat ovarian granulosa cells ( | 0.09, 0.27, and 0.81 g/kg BW, i.g., for 7 days | Decrease apoptosis by reducing ROS production and improving mitochondrial membrane potential through downregulating p53, Bax, caspase-3, and caspase-9 and upregulating Bcl-2; weaken phosphorylation of JNK and p38 MAPK; enhance ERK1/2 phosphorylation | [ | |
| Water-soluble proteins from | Hydroxyl, DPPH, and superoxide anion radicals and reducing power ( | 1-5 mg/mL; 2-10 mg/mL; 8-16 mg/mL | Weak radical-scavenging capacities towards hydroxyl, DPPH, and superoxide anion as well as reducing power to ferric iron | [ | |
| Ethanol-induced oxidative stress in mice ( | 0.1, 0.2, and 0.4 g/kg BW, i.g., for 30 days | Increase T-SOD and GSH; decrease MDA and PCO | |||
| Four proteins from | DPPH and hydroxyl radicals and phosphatidylcholine liposome ( | 0.01-10 mg/mL | Water-soluble and salt-soluble proteins possess stronger | [ | |
| Two polypeptides from | DPPH, hydroxyl, and superoxide anion radicals ( | 2-12 mg/mL | Polypeptide with molecular weight of 1~5 kDa exerts stronger | [ | |
|
| DPPH, hydroxyl, and superoxide anion radicals ( | 2-10 mg/mL | Water-soluble proteins display stronger | [ | |
| Compound Renshen-Hamayou capsule | Aging rats ( | 1.25 g/kg BW, i.g., for 60 days | Decrease MDA; increase GSH-Px activity | [ | |
| Compound Linwayou granule | X-ray-induced oxidative stress in mice ( | 100 and 200 mg/kg BW, i.g., for 7 days | Increase SOD and GSH-Px activities | [ | |
| Antifatigue activities |
| Mice ( | 0.25, 0.5, and 1.0 g/kg BW, i.g., for 30 days | Prolong the endurance time of FST, increase liver glycogen, and decrease BLA | [ |
|
| Hydrocortisone-induced kidney Yang deficiency syndrome in mice ( | OR: 680 mg/kg BW; PEEOR: 136 mg/kg BW for 7 days | OR and PEEOR can increase body temperature and body weight and prolong the endurance time of rotarod test, hypoxia tolerance test, and FST. | [ | |
|
| High-intensity exercise training rats ( | 0.5, 1.0, and 3.0 g/kg BW, i.g., for 6 weeks | Increase body weight, endurance time of FST, testosterone, hemoglobin, and hepatic and muscle glycogen; decrease BUN | [ | |
| Water-soluble proteins from | Mice ( | 0.075, 0.15, and 0.3 g/kg BW, i.g., for 30 days | Increase hepatic glycogen; decrease BLA | [ | |
| Protein hydrolysates from | Mice ( | 0.052, 0.52, and 1.56 g/kg BW, i.g., for 30 days | Increase the endurance time of FST; decrease BUN and BLA | [ | |
| Peptides from | Mice ( | 100, 200, and 400 mg/kg BW, i.g., for 30 days | Prolong the endurance time of FST, rotarod test, and pole-jumping test; reduce BUN and BLA | [ | |
| Water-insoluble components from | Mice ( | 0.25, 0.5, and 1.0 g/kg BW, i.g., for 30 days | Increase the endurance time of FST and hepatic glycogen; decrease BLA | [ | |
| Linwayou soft capsule | Mice ( | 1.0, 2.0, and 3.0 g/kg BW, i.g., for 30 days | Increase the endurance time of FST and hepatic glycogen; decrease BLA and BUN | [ | |
| Compound Linwayou-Yuhuangmo capsule | Mice ( | 0.7, 1.4, and 2.1 g/kg BW, i.g., for 30 days | Increase the endurance time of FST and hepatic glycogen; decrease BLA and BUN | [ | |
| Antiaging activities |
|
| 0.34 and 0.68 mg/g culture medium | Increase life-span, resistance to cold, and lipofuscin | [ |
|
|
| 0.1, 0.2, and 0.4 g/kg BW, i.g., for 43 days | Decrease MDA and XOD; increase MPO and NO | [ | |
|
|
| 0.45, 0.9, and 1.8 g/kg BW, i.g., for 28 days | Upregulate the expressions of cyclin D1, CDK6, and p15; downregulate p16 and p21 | [ | |
| Water-soluble proteins from |
| 0.075, 0.15, and 0.30 g/kg BW, i.g., for 30 days | Decrease MDA; increase SOD | [ | |
| Water-insoluble constituents from |
| 0.15 and 0.3 g/kg BW, i.g., for 30 days | Water-insoluble constituents from | [ | |
| Hamayou capsule |
| 1.4 and 2.8 g/kg BW, i.g., for 28 days | Alleviate pathological changes of ovary and uterus; increase SOD, organ indexes of ovarian and uterine, estradiol and estrous cycle; decrease MDA | [ | |
| Estrogen-like activities | Serum from | Rat ovarian granulosa cells ( | 4.5 g/kg BW, i.g., for 5 days | Increase proliferation and E2 secretion, inhibit apoptosis, and protect ovarian granulosa cells | [ |
|
| Mice ( | 0.05 and 0.2 g/kg BW, i.g., for 37 days | Increase E2, FSH, T, and P; increase the thickness of uterine wall and the number of corpora atretica; enhance the expression of FSHR gene | [ | |
| Compound | Ovariectomized rats ( | 0.5, 1.0, and 2.0 g/kg BW, i.g., for 12 weeks | Increase E2, T, P, and IL-2; decrease FSH and LH; enhance the expression of ER | [ | |
| Hepatoprotective activities |
| CCl4-induced liver fibrotic rats ( | 1.5 and 3.0 g/kg BW, i.g., for 8 weeks | Decrease ALT, AST, ALP, GGT, Hyp, and MDA; increase SOD and GSH-Px | [ |
|
| Ethanol-induced liver fibrotic rats ( | 3 g/kg BW, i.g., for 8 weeks | Increase glycogen granule; hepatocyte nuclear appeared to be large and round. | [ | |
|
| High-intensity exercise training mice ( | 0.9, 4.5, and 9.0 g/kg BW, i.g., for 28 days | Decrease MDA in the liver, increase SOD in the liver, and improve the ultrastructure of impaired hepatic cells | [ | |
| Hypolipidemic activities |
| High-fat-diet-induced hyperlipidemic rats ( | 0.05, 0.1, and 0.2 g/kg BW, i.g., for 30 days | Decrease TC and TG | [ |
| Water-insoluble constituents and their hydrolysates from | High-fat-diet-induced hyperlipidemic rats ( | 0.05, 0.1, and 0.2 g/kg BW, i.g., for 30 days | Decrease TC and TG; the effects of hydrolysates were superior to water-insoluble constituents. | [ | |
| Water-soluble proteins from | High-fat-diet-induced fatty rats ( | 0.05, 0.1, and 0.2 g/kg BW, i.g., for 30 days | Decrease TC and TG | [ | |
| Antiosteoporotic activities |
| Ovariectomized rats ( | 0.05 g/kg BW, i.g., for 12 weeks | Increase calcium, estrogen, BMD, bone scan index, femoral weight, W.th, and osteocalcin; decrease ALP, phosphorus, and BGP; enhance the proliferation of osteoblastic cells and the formation of mineralized nodes; reduce the number of TRAP-positive cells | [ |
|
| Women with postmenopausal osteoporosis ( | 1 g per day, P.O., for 6 months | Improve clinical signs and symptoms; increase E2; decrease BALP, IL-6, and BGP | [ | |
| Antidepressant activities | Petroleum ether extract of | Behavioral despair model of depression in mice ( | 100, 300, and 900 mg/kg BW, i.g., for 8 days | Decrease the dead time of FST and TST, CORT, and akinesia; increase body temperature | [ |
| Petroleum ether extract of | Chronic mild stress model of depression in rats ( | 30, 100, and 300 mg/kg BW, i.g., for 21 days | Increase body weight, motion distance of OFT, and sucrose preference; decrease CORT; upregulate the expression of BDNF protein | [ | |
| 1-Methylhydantoin | Chronic forced swim stress-induced depression in rats ( | 20, 40, and 80 mg/kg BW, i.g., for 14 days | Increase body weight and sucrose preference; decrease CORT; upregulate the expression of BDNF protein | [ | |
| Antitussive, expectorant, antiasthmatic, and anti-inflammatory activities |
| Sulfur dioxide and ammonia-induced cough in mice ( | OR: 680 mg/kg BW; PEEOR: 68 and 136 mg/kg BW; MEOR: 85 and 170 mg/kg BW, i.g., for 3 and 7 days, respectively | Prolong the incubation period of cough and reduce cough frequency (efficiency: OR > MEOR > PEEOR); increase phenol red expectoration (efficiency: OR > PEEOR > MEOR) and sputum ejection (efficiency: PEEOR > OR > MEOR) | [ |
|
| Ovalbumin-induced allergic asthma in mice ( | 0.05 and 0.5 g/kg BW, i.g., for 8 weeks | Decrease inflammatory cell count, IL-4, IL-5, and IFN- | [ | |
| 1-Methylhydantoin | Ovalbumin-induced allergic asthma in rats ( | 40 and 80 mg/kg BW, i.g., for 7 days | Decrease IL-5, eotaxin, and eosinophil count in BALF | [ | |
| Acetylcholine-induced bronchial asthma in guinea pigs ( | 30 and 60 mg/kg BW, i.g., for 3 days | Prolong the incubation period of asthma | |||
| Histamine-induced contraction of guinea pig tracheal smooth muscle ( | 0.5 and 1.0 g/L | Increase antispasmodic percentage | |||
| Ammonia-induced cough in mice ( | 50 and 100 mg/kg BW, i.g., for 3 days | Prolong the incubation period of cough and reduce cough frequency | |||
| Citric acid-induced cough in guinea pigs ( | 30 and 60 mg/g BW, i.g., for 3 days | Prolong the incubation period of cough and reduce cough frequency | |||
| Anticancer activities | Protein hydrolysates from | Human glioma C6 cell ( | 500 | Inhibit glioma cell proliferation and colony formation; promote apoptosis in glioma cell; downregulate Bcl-2; upregulate Bax and cleaved caspase-3 | [ |
| Glioma model in nude mice ( | 1.5 g/kg BW, i.g. | Inhibit glioma growth; increase IL-1 |
Abbreviations: BW: body weight; i.g.: intragastric administration; CD: cluster of differentiation; IL-2: interleukin-2; NK: natural killer; NO: nitric oxide; IL-1β: interleukin-1β; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α; NF-κB: nuclear factor-κB; mRNA: messenger ribonucleic acid; iNOS: inducible nitric oxide synthase; P.O.: oral administration; T-SOD: total superoxide dismutase; SOD: superoxide dismutase; MDA: malondialdehyde; PCO; GPx4: glutathione peroxidase 4; ROS: reactive oxygen species; MAPK: mitogen-activated protein kinases; DPPH: 1,1-diphenyl-2-picrylhydrazyl; GSH: glutathione; GSH-Px: glutathione peroxidase; FST: forced swimming test; BUN: blood urea nitrogen; BLA: blood lactic acid; H2O2: hydrogen peroxide; XOD: xanthine oxidase; MPO: myeloperoxidase; CDK-6: cyclin-dependent kinases-6; E2: estradiol; FSH: follicle-stimulating hormone; T: testosterone; P: progesterone; FSHR: follicle-stimulating hormone receptor; TβRI: type I transform growth factor β receptor; TβRII: type II transform growth factor β receptor; LH: luteinizing hormone; ER: estrogen receptor; ALT: alanine aminotransferase; AST: glutamic-oxalacetic transaminase; ALP: alkaline phosphatase; GGT, γ-glutamyltransferase; Hyp: hydroxyproline; CCl4: carbon tetrachloride; TC: total cholesterol; TG: triglyceride; BGP: bone gla protein; BMD: bone mineral densities; W.th: wall thickness; TRAP: tartrate-resistant acid phosphatase; BALP: bone alkaline phosphatase; IL-6: interleukin-6; Runx2: runt-related transcription factor 2; BMP2: bone morphogenetic protein 2; TST: tail suspension test; CORT: corticosterone; OFT: open field test; BDNF: brain-derived neurotrophic factor; PEEOR: petroleum ether extract from Oviductus ranae; MEOR: methanol extract from Oviductus ranae; IL-4: interleukin-4; IL-5: interleukin-5; IFN-γ: interferon-γ; BALF: bronchial alveolus lavage fluid; IL-1β: interleukin-1β.
Figure 4Hydrogen-donor side chains of amino acids present in WPOR [84].
Safety properties of Oviductus ranae and its active principle as well as preparations.
| Active principle/preparation | Main constituents | Tests | Model | Dosage | Results | Reference |
|---|---|---|---|---|---|---|
| Raw material |
| Acute toxicity | Mice ( | 2.5-20 g/kg BW, i.g., single-dose administration, followed by an observation of 14 days | MTD > 20 g/kg BW | [ |
| Subacute toxicity | Rats ( | 1.75, 3.5, and 7 g/kg BW, i.g., for 28 days | NOAEL > 7 g/kg BW | |||
| Ames test |
| 8-5000 | None | |||
| Micronucleus test | Mice ( | 2.5, 5, and 10 g/kg BW, i.g., for 2 days | None | |||
| Sperm malformation assay | Mice ( | 2.5, 5, and 10 g/kg BW, i.g., for 5 days, followed by an observation of 30 days | None | |||
| Active principle | Protein-rich extract from | Acute toxicity | Mice ( | 5, 10, and 20 g/kg BW, i.g., single-dose administration, followed by an observation of 14 days | MTD > 20 g/kg BW | [ |
| Compound Danggui-Shuangshen-Hamayou tablet | Ginseng, | Acute toxicity | Mice ( | 20 g/kg BW, i.g., single-dose administration, followed by an observation of 7 days | MTD > 20 g/kg BW | [ |
| Micronucleus test | Mice ( | 2.5, 5, and 10 g/kg BW, i.g., for 2 days | None | |||
| Sperm malformation assay | Mice ( | 2.5, 5, and 10 g/kg BW, i.g., for 5 days, followed by an observation of 30 days | None | |||
| Hamayou soft capsule |
| Ames test |
| 0.313-5 g/plate | None | [ |
| Micronucleus test | Mice ( | 0.94-7.5 g/kg BW, i.g., for 4 days | None | |||
| Sperm malformation assay | Mice ( | 1.88, 3.75, and 7.5 g/kg BW, i.g., for 5 days, followed by an observation of 30 days | None |
Abbreviations: BW: body weight; i.g.: intragastric administration; MTD: maximal tolerated dose; NOAEL: no-observed-adverse-effect levels.
Current functional foods based on Oviductus ranae on the market approved by the China Food and Drug Administration.
| Brand ® | Dosage form | Main constituents | Health functions | Approval number |
|---|---|---|---|---|
| Tongrentang | Granule |
| Antifatigue and immune enhancement | SHIJIANZI 2002-0060 |
| Shiyuan | Granule |
| Antifatigue and immune enhancement | SHIJIANZI G20130137 |
| Yishoutang | Soft capsule |
| Blood lipid regulation and antiaging | SHIJIANZI 2002-0193 |
| Yicaotang | Liquid |
| Antifatigue and immune enhancement | SHIJIANZI G20150785 |
| Biyuantang | Soft capsule |
| Antifatigue | SHIJIANZI G20100381 |
| Xuejian | Soft capsule |
| Antifatigue | SHIJIANZI 2002-0620 |
| Jizhensanbao | Soft capsule |
| Immune enhancement | SHIJIANZI G20130091 |
| Wantong | Liquid |
| Immune enhancement | SHIJIANZI 2003-0219 |
| Xingjing | Capsule |
| Immune enhancement | SHIJIANZI 2002-0024 |
| Chunyuanwabao | Granule |
| Immune enhancement and antifatigue | SHIJIANZI G20150654 |
| Yisheng | Powder |
| Immune enhancement | SHIJIANZI G20120426 |
| Shengjixin | Granule |
| Immune enhancement and antifatigue | SHIJIANZI G20150940 |
| Yuanbo | Soft capsule |
| Antifatigue | SHIJIANZI G20120244 |
| Yuanbo | Soft capsule |
| Immune enhancement | SHIJIANZI G20110405 |
| Dongfangyaolin | Tablet |
| Antichloasma | SHIJIANZI G20100592 |
| Tangsong | Soft capsule |
| Immune enhancement | SHIJIANZI G20140677 |
| Hongming | Soft capsule |
| Antifatigue | SHIJIANZI G20040428 |
| Beijiang | Capsule |
| Immune enhancement | SHIJIANZI 2003-0258 |
| Yongli | Soft capsule |
| Antifatigue | SHIJIANZI 2000-0219 |
| Jizhu | Soft capsule |
| Immune enhancement | SHIJIANZI G20041071 |
The information was obtained from http://samr.cfda.gov.cn/WS01/CL0001/; the search keywords were “Oviductus ranae”, “Hamayou”, and “Hashimayou”.
Some investigational nutraceutical products based on Oviductus ranae.
| Preparation name | Dosage form | Main constituents | Function | References |
|---|---|---|---|---|
| Compound Linwayou-Renshen capsule | Capsule |
| Antioxidation | [ |
| Yifuning soft capsule | Soft capsule |
| Treat climacteric syndrome and postmenopausal osteoporosis | [ |
| Compound Liuwei Xueha tablet | Tablet |
| Antiaging and antioxidant activities | [ |
| Compound Renshen-Hamayou capsule | Capsule |
| Immune enhancement | |
| Shenlai tablet | Tablet |
| Antifatigue | [ |
| Compound Linwayou-Yuhuangmo capsule | Capsule |
| Antifatigue | [ |
| Compound Linwayou granule | Granule |
| Radiation protection | [ |
| Compound Linwayou-Pingbeimu soft capsule | Soft capsule |
| Immune enhancement | [ |
| Compound Suanzaoren-Linwayou capsule | Capsule |
| Improve sleep | [ |
| Linwayou moisturizing emulsion | Emulsion |
| Moisturizing and sunscreening | [ |
| Compound Renshen-Linwayou soft capsule | Soft capsule |
| Antifatigue | [ |